Background -H1 antihistamines have been shown to have an antitussive effect in patients with asthma, postnasal drip, and allergic rhinitis. No study has been performed to determine whether orally administered H1 antihistamines can reduce the number of coughs induced by stimulation of cough receptors in non-asthmatic patients with chronic dry cough. Methods -The effect of loratadine (10 mg) on the number of coughs induced by ultrasonically nebulised distilled water (UNDW) was examined in 10 patients with nasal disease and in seven patients with unexplained chronic cough using a randomised, double blind crossover method. Eleven normal volunteers were also studied. Each subject inhaled UNDW for one minute, and the numbers of coughs during the one minute inhalation and the 30 seconds following it were counted. Results -There was no difference in the results of pulmonary function tests performed before and one minute after UNDW inhalation for either patients or normal subjects. There was also no significant difference between the results of pulmonary function tests before or after oral administration of loratadine. Loratadine significantly reduced the number of coughs in patients with nasal disease and in those with unexplained chronic cough, but not in normal subjects. Conclusions -The H1 antihistamine loratadine reduces cough induced by UNDW. The release of histamine may contribute to the chronic cough in patients with unexplained chronic cough or nasal disease.
Chronic cough of unknown cause is a common clinical problem. Specific treatments have been devised for patients with chronic cough with postnasal drip, asthma, and gastro-oesophageal reflux.' Pratter et al have reported an algorithm for the treatment of chronic cough and suggest that an H, antihistamine may be effective and that bronchoprovocation challenge is useful in investigation.2 The newer non-sedating antihistamines such as loratadine and terfenadine may be clinically useful for patients with chronic cough.3)5
Ultrasonically nebulised distilled water (UNDW) inhalation can induce bronchoconstriction in asthmatic subjects and this bronchoconstriction can be inhibited with H1 antihistamines, inhaled anticholinergic agents, D agonists, and disodium cromoglycate.5-10 Protection against this bronchoconstriction may be independent of bronchodilation since it has been reported that oral terfenadine is a more effective inhibitor of distilled water-induced bronchoconstriction than is inhaled ipratropium bromide.7 Bronchoconstriction associated with UNDW inhalation in asthmatic subjects is thought to occur as a result of direct osmotic changes in the mucosa or lining fluid that may change wall thickness, together with osmotically stimulated local mediator re- lease." 12 However, in non-asthmatic subjects inhalation of UNDW has no direct effect on the size of the airway.'2 UNDW-induced cough is not caused by bronchoconstriction and is inhibited by inhaled lignocaine,5 inhaled anticholinergic bronchodilators, and c adrenergic agonists.l3 However, the effect of HI antihistamine on UNDW-induced cough has not been systematically studied in non-asthmatic patients with chronic cough.
The aim of this study was to determine whether H1 antihistamines, which are widely used antiallergic drugs, can reduce the number of coughs induced by UNDW inhalation in non-asthmatic patients with chronic cough and in normal volunteers, and whether they have an acute effect on the results of pulmonary function tests.
Methods

SUBJECTS
The three groups of subjects who took part in the study comprised 10 non-asthmatic patients with chronic cough and a history of nasal disease, seven non-asthmatic patients with unexplained chronic cough and no nasal disease, and 11 normal subjects. All patients and subjects were non-smokers.
The 10 patients (four men) with nasal disease were aged years and had chronic cough of more than eight weeks duration. Four had a history of allergic rhinitis only, four had postnasal drip only, and two had a history of both allergic rhinitis and postnasal drip (table  1) . The six patients with a history of allergic rhinitis had neither nasal discharge nor sneezing at the time of the study.
The seven non-asthmatic patients (two men) without nasal disease were aged 27-61 years (FVC) , forced expiratory volume in one second (FEV1), and maximum expiratory flow at 25% vital capacity (V25)) were performed every two minutes before and after UNDW inhalation with a Chestac-25 F System (Chest Co Ltd, Tokyo, Japan).
METHACHOLINE CHALLENGE
The methacholine provocation challenge test was performed three or five days before UNDW inhalation using the method described by Makino et al. 6 In brief, aerosols were generated with a nebuliser at an air flow rate of 5 1/min. At five minute intervals each subject inhaled the aerosol for two minutes during quiet breathing through the mouth. An isotonic 0.9% saline solution was inhaled first, followed by methacholine in concentrations ranging from 20 to 10 000 ,ug/ml in doubling increments. The FEVy was measured before and after inhalation of the saline solution and after each inhalation of methacholine. When the change in FEV, from the baseline after the inhalation of saline was 10% or less in all subjects, inhalation of methacholine was started.
The test was continued until the FEV, had fallen by 20% or until the highest concentration of methacholine had been administered. The threshold was defined as the lowest concentration of methacholine that produced a 20% fall in FEV, (PC20) which was calculated by linear interpolation between the last two data points on the dose-response curve or was expressed as 10 000 gg/ml if there had been no response.
STUDY DESIGN
A randomised, double blind, crossover method was used. In the afternoon of the visit to the laboratory on day 1 each subject inhaled UNDW for one minute and the number of coughs during the inhalation and the 30 seconds following it were counted. One tablet of loratadine (10 mg, Schering-Plough, Osaka, Japan) or one tablet of an identical placebo (starch) were then administered in a randomised double blind fashion. One hour later one minute UNDW inhalation was repeated and the number of coughs was again counted. Intervals of one hour between UNDW inhalations were used because of the pharmacokinetics of loratadine.3 The second day of the study was two days after day 1. Each subject inhaled UNDW for one minute and the number of coughs was counted. Placebo or loratadine were then administered, whichever had not been given on day 1. One hour later one minute UNDW inhalation was performed and the numbers of coughs were counted again.
STATISTICAL ANALYSES
The results are expressed as mean (SD) but the numbers of coughs, FEVI, and V25 values are expressed as mean (SE). Comparison of pretreatment UNDW challenges between days 1 and 2 was performed using a two tailed Student's t test. The repeatability of the pretreatment UNDW cough challenges was assessed using the method of Bland and Altman.'7 The mean number of coughs on days 1 and 2 was plotted against the difference between the means, both expressed on a logarithmic scale. Pretreatment differences in the number of coughs between groups were examined using the Mann-Whitney U test. Differences in the numbers of coughs from baseline to treatment were analysed using the Wilcoxon's rank sum test which compared intragroup differences.
The Mann-Whitney U test was used to compare differences in the numbers of coughs from control to treatment between the different groups. Changes in recorded FEV, and V25
were analysed using analysis of variance (ANOVA). Values of p < 0.05 were taken to indicate statistical significance.
Results
There was no significant difference in the number of coughs before treatment on days 1 and 2. The calculated coefficient of repeatability for the UNDW challenge was 0.21 ( fig 1) . Tachyphylaxis did not occur during the one minute UNDW inhalation in any of the patients or the normal subjects. The two groups ofpatients with chronic cough each had a significantly larger response to UNDW inhalation testing than did the normal subjects ( fig  2) . Neither placebo nor loratadine had any effect on the number of coughs in normal subjects and placebo had no effect in either of the patient groups. However, compared with placebo, loratadine significantly reduced the number of coughs in both patients with nasal disease (p = 0.005) and those with unexplained chronic cough (p < 0.05) (fig 3) . There was no difference in the amount of cough reduction between the two groups of patients. Since there was no significant difference in FEV1 or V25 before and after UNDW inhalation or before and after oral administration of placebo or loratadine in either patients or normal subjects, loratadine had no acute effect on bronchodilation one hour after its oral administration. Patients exhibited no hyperresponsiveness on methacholine challenge tests.
Discussion
The findings of this study show that, for non-asthmatic patients with chronic cough, the HI antihistamine loratadine, when given orally in a dose of 10 mg, significantly reduces cough induced by UNDW inhalation. This finding is important because it provides indirect evidence that, in at least some patients with chronic cough and a history of nasal diseases and some with unexplained chronic cough and no nasal disease, histamine release in response to a change in osmolarity of the airways contributes to the cough. Loratadine, when orally administered an hour before pulmonary function tests, had no acute bronchodilating effects in this study. It is clear that cough and bronchoconstrictor reflexes are mediated through different afferent neural pathways.7 18-20 However, it has been shown that the bronchodilating effect may be one of the reasons for inhibition of cough induced by UNDW inhalation in normal volunteers, in 
, and in those with asthma.'3 21 22 If coughing in the patient groups receives a contribution from heightened perception due to conductance changes, HI antihistamines can decrease specific airways conductance, thereby increasing FEV, or V25. A previous study reported that both distilled water and hypertonic saline produced small increases in non-specific reactivity in non-asthmatic subjects and confirmed that substantial osmotic challenge does not change airway calibre.'2 Although the authors of that study used a larger amount of UNDW than in our study, in four subjects V25 was measured and had a plateau similar to that of specific airways conductance.'2 In our study FEV, and V25 were not significantly changed in either the patients or the normal subjects. Our findings suggest that loratadine reduces the number of coughs induced by UNDW inhalation by an H, antihistamine effect rather than by an anticholinergic effect.
The patient groups had a significantly larger response to UNDW inhalation than did normal subjects which indicated that both patients with nasal disease and those with unexplained chronic cough had a higher degree of cough sensitivity than normal subjects. In a study in which three minute UNDW inhalations with 30 minute intervals between inhalations were used, tachyphylaxis occurred in normal subjects. ' Figure 3 Effect of oral administration of loratadine on the number of coughs induced by UNDW inhalation in (A) normal subjects, (B) patients with nasal disease, and (C) patients with unexplained chronic cough. 
